Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor cell vaccine (NGEN-143) activates T cells that ...

Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

In April 2025, Areteia Therapeutics announced a study will assess the efficacy and safety of dexpramipexole as an adjunctive ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems, shared key findings from its latest mRNA-LNP therapeutic research during the recent 2025 World Vaccine Congress, held in ...

Intraocular inflammation was evaluated by histopathological scoring. Frequencies of Th1/Th17 cells were measured by flow cytometry. Concentrations of IFN-γ/IL-17A, neutrophil elastase (NE) and ...

Conclusion Our findings suggest that IL-12-mediated co-activation of STAT1 and STAT4 alters histone modification, resulting in differentiation of Tfh-Th1-like cells that are characteristically ...